Profound Ebit Per Revenue vs Capex To Revenue Analysis

PROF Stock

USD 7.84 0.32 4.26%

Profound Medical financial indicator trend analysis is much more than just breaking down Profound Medical Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Profound Medical Corp is a good investment. Please check the relationship between Profound Medical Ebit Per Revenue and its Capex To Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profound Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Profound Medical Corp Ebit Per Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between Profound Medical's Ebit Per Revenue and Capex To Revenue is 0.09. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Profound Medical Corp, assuming nothing else is changed. The correlation between historical values of Profound Medical's Ebit Per Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Profound Medical Corp are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ebit Per Revenue i.e., Profound Medical's Ebit Per Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.09

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebit Per Revenue

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Profound Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Profound Medical Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profound Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

At this time, Profound Medical's Sales General And Administrative To Revenue is most likely to increase slightly in the upcoming years. The Profound Medical's current Enterprise Value is estimated to increase to about 206.9 M, while Selling General Administrative is projected to decrease to roughly 6.9 M.

	2021	2022	2023	2024 (projected)
Interest Expense	303K	174K	932.8K	731.0K
Depreciation And Amortization	1.9M	1.6M	1.1M	1.1M

Interest Expense Depreciation And Amortization

Profound Medical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets
Total Assets		0.03	0.59	0.51	0.99	0.85	0.71	-0.97	-0.77	0.72	0.99	0.66	0.83	0.67	0.99	0.68	0.85	0.88	0.18	0.68	0.92	0.5	0.55	1.0	-0.14	0.36
Short Long Term Debt Total	0.03		0.65	0.6	-0.12	0.34	0.5	0.19	-0.38	0.39	-0.07	0.2	-0.38	0.01	-0.07	0.2	0.34	0.31	0.92	0.54	-0.04	0.82	0.43	0.0	0.53	0.35
Other Current Liab	0.59	0.65		0.76	0.47	0.62	0.67	-0.42	-0.65	0.78	0.5	0.59	0.24	0.26	0.52	0.47	0.7	0.65	0.67	0.77	0.39	0.88	0.62	0.56	0.21	0.63
Total Current Liabilities	0.51	0.6	0.76		0.38	0.82	0.74	-0.32	-0.67	0.94	0.4	0.76	0.19	0.4	0.39	0.55	0.7	0.65	0.48	0.81	0.32	0.91	0.74	0.46	0.72	0.8
Total Stockholder Equity	0.99	-0.12	0.47	0.38		0.78	0.62	-0.99	-0.69	0.62	1.0	0.6	0.89	0.67	1.0	0.64	0.78	0.82	0.05	0.57	0.93	0.35	0.45	0.99	-0.26	0.26
Property Plant And Equipment Net	0.85	0.34	0.62	0.82	0.78		0.84	-0.73	-0.8	0.88	0.79	0.78	0.59	0.72	0.77	0.72	0.86	0.87	0.35	0.8	0.74	0.75	0.68	0.82	0.37	0.58
Current Deferred Revenue	0.71	0.5	0.67	0.74	0.62	0.84		-0.54	-0.92	0.78	0.63	0.51	0.35	0.44	0.63	0.67	0.91	0.92	0.55	0.92	0.61	0.8	0.8	0.7	0.33	0.3
Net Debt	-0.97	0.19	-0.42	-0.32	-0.99	-0.73	-0.54		0.61	-0.57	-0.99	-0.59	-0.92	-0.67	-0.99	-0.59	-0.71	-0.77	0.02	-0.49	-0.91	-0.28	-0.36	-0.97	0.32	-0.25
Retained Earnings	-0.77	-0.38	-0.65	-0.67	-0.69	-0.8	-0.92	0.61		-0.76	-0.7	-0.44	-0.36	-0.29	-0.7	-0.71	-0.98	-0.94	-0.5	-0.92	-0.71	-0.73	-0.88	-0.77	-0.18	-0.25
Accounts Payable	0.72	0.39	0.78	0.94	0.62	0.88	0.78	-0.57	-0.76		0.63	0.84	0.46	0.5	0.62	0.63	0.82	0.78	0.36	0.82	0.52	0.84	0.77	0.68	0.48	0.79
Cash	0.99	-0.07	0.5	0.4	1.0	0.79	0.63	-0.99	-0.7	0.63		0.6	0.87	0.67	1.0	0.64	0.79	0.83	0.09	0.59	0.92	0.39	0.46	0.99	-0.25	0.28
Non Current Assets Total	0.66	0.2	0.59	0.76	0.6	0.78	0.51	-0.59	-0.44	0.84	0.6		0.64	0.74	0.59	0.33	0.54	0.58	0.14	0.53	0.52	0.6	0.39	0.6	0.33	0.86
Non Currrent Assets Other	0.83	-0.38	0.24	0.19	0.89	0.59	0.35	-0.92	-0.36	0.46	0.87	0.64		0.79	0.87	0.33	0.48	0.55	-0.3	0.29	0.73	0.06	0.17	0.82	-0.33	0.25
Other Assets	0.67	0.01	0.26	0.4	0.67	0.72	0.44	-0.67	-0.29	0.5	0.67	0.74	0.79		0.66	0.27	0.4	0.48	-0.06	0.33	0.55	0.28	0.16	0.64	0.09	0.4
Cash And Short Term Investments	0.99	-0.07	0.52	0.39	1.0	0.77	0.63	-0.99	-0.7	0.62	1.0	0.59	0.87	0.66		0.62	0.79	0.82	0.09	0.6	0.92	0.38	0.45	0.99	-0.27	0.26
Net Receivables	0.68	0.2	0.47	0.55	0.64	0.72	0.67	-0.59	-0.71	0.63	0.64	0.33	0.33	0.27	0.62		0.74	0.75	0.36	0.53	0.6	0.54	0.66	0.7	0.16	0.31
Common Stock Total Equity	0.85	0.34	0.7	0.7	0.78	0.86	0.91	-0.71	-0.98	0.82	0.79	0.54	0.48	0.4	0.79	0.74		0.95	0.45	0.91	0.76	0.73	0.88	0.84	0.15	0.33
Common Stock Shares Outstanding	0.88	0.31	0.65	0.65	0.82	0.87	0.92	-0.77	-0.94	0.78	0.83	0.58	0.55	0.48	0.82	0.75	0.95		0.46	0.84	0.84	0.7	0.73	0.88	0.08	0.33
Non Current Liabilities Total	0.18	0.92	0.67	0.48	0.05	0.35	0.55	0.02	-0.5	0.36	0.09	0.14	-0.3	-0.06	0.09	0.36	0.45	0.46		0.54	0.19	0.78	0.46	0.17	0.25	0.25
Other Current Assets	0.68	0.54	0.77	0.81	0.57	0.8	0.92	-0.49	-0.92	0.82	0.59	0.53	0.29	0.33	0.6	0.53	0.91	0.84	0.54		0.57	0.86	0.82	0.66	0.38	0.39
Other Stockholder Equity	0.92	-0.04	0.39	0.32	0.93	0.74	0.61	-0.91	-0.71	0.52	0.92	0.52	0.73	0.55	0.92	0.6	0.76	0.84	0.19	0.57		0.36	0.38	0.93	-0.28	0.18
Total Liab	0.5	0.82	0.88	0.91	0.35	0.75	0.8	-0.28	-0.73	0.84	0.39	0.6	0.06	0.28	0.38	0.54	0.73	0.7	0.78	0.86	0.36		0.72	0.46	0.56	0.66
Property Plant And Equipment Gross	0.55	0.43	0.62	0.74	0.45	0.68	0.8	-0.36	-0.88	0.77	0.46	0.39	0.17	0.16	0.45	0.66	0.88	0.73	0.46	0.82	0.38	0.72		0.53	0.4	0.35
Total Current Assets	1.0	0.0	0.56	0.46	0.99	0.82	0.7	-0.97	-0.77	0.68	0.99	0.6	0.82	0.64	0.99	0.7	0.84	0.88	0.17	0.66	0.93	0.46	0.53		-0.2	0.29
Short Term Debt	-0.14	0.53	0.21	0.72	-0.26	0.37	0.33	0.32	-0.18	0.48	-0.25	0.33	-0.33	0.09	-0.27	0.16	0.15	0.08	0.25	0.38	-0.28	0.56	0.4	-0.2		0.53
Intangible Assets	0.36	0.35	0.63	0.8	0.26	0.58	0.3	-0.25	-0.25	0.79	0.28	0.86	0.25	0.4	0.26	0.31	0.33	0.33	0.25	0.39	0.18	0.66	0.35	0.29	0.53

Click cells to compare fundamentals

Profound Medical Account Relationship Matchups

Profound Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	29.9M	104.6M	86.8M	64.4M	43.7M	46.2M
Short Long Term Debt Total	13.0M	1.7M	1.4M	8.2M	7.9M	6.9M
Other Current Liab	530.0K	744K	248K	621K	714.2K	537.7K
Total Current Liabilities	8.2M	4.8M	4.2M	4.2M	6.4M	5.1M
Total Stockholder Equity	14.3M	97.4M	80.6M	52.0M	31.2M	36.2M
Property Plant And Equipment Net	2.2M	2.3M	1.9M	1.7M	1.5M	1.4M
Current Deferred Revenue	501.2K	358K	477K	471K	721K	384.1K
Net Debt	(3.8M)	(82.2M)	(65.8M)	(38.3M)	(18.2M)	(19.1M)
Retained Earnings	(100.3M)	(130.0M)	(160.7M)	(189.4M)	(217.9M)	(207.0M)
Accounts Payable	3.0M	3.4M	3.2M	2.0M	3.3M	2.6M
Cash	14.7M	83.9M	67.2M	46.5M	26.2M	32.4M
Non Current Assets Total	7.2M	6.9M	9.7M	2.4M	2.0M	1.9M
Cash And Short Term Investments	14.7M	83.9M	67.2M	46.5M	26.1M	33.2M
Net Receivables	3.3M	8.2M	1.4M	6.3M	7.3M	3.8M
Common Stock Total Equity	98.4M	120.9M	130.3M	211.5M	243.3M	255.4M
Common Stock Shares Outstanding	11.1M	17.3M	20.5M	20.8M	21.2M	12.5M
Liabilities And Stockholders Equity	29.9M	104.6M	86.8M	64.4M	43.7M	46.2M
Non Current Liabilities Total	7.4M	2.4M	2.0M	8.2M	6.4M	5.2M
Other Current Assets	1.0M	296.0K	1.1M	1.2M	1.6M	1.7M
Other Stockholder Equity	15.0M	73.2M	80.8M	85.7M	19.7M	32.6M
Total Liab	15.6M	7.3M	6.2M	12.4M	12.7M	10.1M
Total Current Assets	22.7M	97.7M	77.1M	62.0M	41.9M	41.4M
Accumulated Other Comprehensive Income	(89.7K)	4.6M	4.7M	16.8M	12.0M	12.6M
Short Term Debt	4.1M	312K	250K	762K	2.4M	1.7M
Intangible Assets	2.4M	1.9M	1.4M	680K	487.5K	463.1K
Common Stock	99.7M	211.5M	219.6M	205.8M	217.4M	135.6M
Other Liab	654K	1.1M	875K	764K	878.6K	1.1M
Net Tangible Assets	9.3M	92.8M	76.5M	51.3M	59.0M	38.0M
Long Term Debt	443.9K	10.6M	6.7M	6.7M	5M	6.1M
Inventory	3.6M	5.3M	7.4M	7.9M	7.0M	4.3M
Short Long Term Debt	4.7M	1.3M	5.1M	523K	2.1M	2.6M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Profound Medical Corp is a strong investment it is important to analyze Profound Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Profound Medical's future performance. For an informed investment choice regarding Profound Stock, refer to the following important reports:

How To Invest In Profound

Details

Is Profound Stock a good investment?

Details

What is Profound Medical's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profound Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Profound Medical. If investors know Profound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Profound Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.34)

Revenue Per Share

0.38

Quarterly Revenue Growth

0.639

Return On Assets

(0.45)

Return On Equity

(0.90)

The market value of Profound Medical Corp is measured differently than its book value, which is the value of Profound that is recorded on the company's balance sheet. Investors also form their own opinion of Profound Medical's value that differs from its market value or its book value, called intrinsic value, which is Profound Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Profound Medical's market value can be influenced by many factors that don't directly affect Profound Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Profound Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Profound Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Profound Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Profound Ebit Per Revenue vs Capex To Revenue Analysis

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Capex To Revenue

Profound Medical fundamental ratios Correlations

Profound Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Profound Medical fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Common Stock Total Equity	- 0.98	Retained Earnings
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets